Endocrine Therapy Omission in Estrogen Receptor–Low (1%-10%) Early-Stage Breast Cancer
DON’T omit, there is still a benefit, especially in 6-10% patients.
Second-Line Endocrine Therapy With or Without Palbociclib Rechallenge in Patients With Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: PALMIRA Trial
Author(s): Antonio Llombart-Cussac, MD, PhD1,2,3; Catherine Harper-Wynne, MD, PhD4; Antonia Perelló, MD, PhD5; Audrey Hennequin, MD, PhD6; Adela Fernández-Ortega, MD, PhD7; Marco Colleoni, MD, PhD8; Sara Marín, MD, PhD2; Vanesa Quiroga, MD, PhD9; Jacques Medioni, MD, PhD10,11; Vega Iranzo, MD, PhD12,13; Duncan Wheatley, MD, PhD14; Sonia del Barco Berrón, MD, PhD15; Antonio Antón, MD, PhD16,17; Erion Dobi, MD, PhD18; Manuel Ruiz-Borrego, MD, PhD19; Daniel Alcalá-López, PhD1; Jhudit Pérez-Escuredo, PhD1; Gabriele Antonarelli, MD, PhD20,21; Miguel Sampayo-Cordero, PhD1; José Manuel Pérez-García, MD, PhD1,22; Javier Cortés, MD, PhD1,22,23,24;
Source: DOI:10.1200/JCO-24-01865
Dr. Maen Hussein's Thoughts
Adding Palbociclib did not help, revealing that there is no need to continue with different hormonal therapy than the one used in first line. It also added more toxicity.
PURPOSE
Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors plus endocrine therapy (ET) represents the standard first-line treatment for patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative (HER2-negative) advanced breast cancer (ABC). However, there is no definitive consensus on the preferred second-line treatment option. The PALMIRA trial investigated whether palbociclib rechallenge with an alternative ET would improve the antitumor activity in patients progressing after a first-line palbociclib-containing regimen.
METHODS
This international, randomized, open-label, phase II study enrolled 198 patients with hormone receptor–positive/HER2-negative ABC with disease progression after first-line palbociclib plus ET (aromatase inhibitor or fulvestrant). Patients were eligible if they showed clinical benefit to the previous regimen (response or stable disease ≥24 weeks) or had progressed on a palbociclib-based therapy in the adjuvant setting. Patients were randomly assigned (2:1 ratio) to either palbociclib rechallenge plus second-line ET (fulvestrant or letrozole) or second-line ET alone. Stratification factors were previous ET and visceral involvement. The primary end point was investigator-assessed progression-free survival (PFS).
RESULTS
Between April 2019 and October 2022, 136 and 62 patients were randomly assigned to palbociclib plus ET or ET alone, respectively. Median investigator-assessed PFS was 4.9 months (95% CI, 3.6 to 6.1) with palbociclib plus ET versus 3.6 months (95% CI, 2.5 to 4.2) with ET alone (hazard ratio, 0.84 [95% CI, 0.66 to 1.07]; P = .149). Grade ≥3 treatment-emergent adverse events were higher with palbociclib plus ET (47.4% v 10.0%), without new safety signals.
CONCLUSION
Palbociclib rechallenge plus an alternative ET did not significantly improve PFS compared with ET alone in patients with hormone receptor–positive/HER2-negative ABC progressing on a first-line palbociclib-based ET regimen.
Author Affiliations
1Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain; 2Hospital Arnau de Vilanova, FISABIO, Valencia, Spain; 3Translational Oncology Group, Medicine Department, Facultad de Ciencias de la Salud, Universidad Cardenal Herrera-CEU, Alfara del Patriarca, Spain; 4Maidstone Hospital – Kent Oncology Centre, Maidstone, United Kingdom; 5Hospital Universitari Son Espases, Palma de Mallorca, Spain; 6Centre Georges François Leclerc, Dijon, France; 7Institut Català d’Oncologia L’Hospitalet (ICO), Barcelona, Spain; 8IEO, Instituto Europeo di Oncologia, IRCCS, Milan, Italy; 9Institut Català d’Oncologia Badalona (ICO), Barcelona, Spain; 10Hôpital Européen Georges Pompidou, Paris, France; 11University Paris Cité, Paris, France; 12Consorci Hospital General Universitari de València, Valencia, Spain; 13Universitat de València, Valencia, Spain; 14Royal Cornwall Hospital NHS Trust, Cornwall, United Kingdom; 15Institut Català d’Oncologia Girona (ICO), Girona, Spain; 16Hospital Universitario Miguel Servet, Zaragoza, Spain; 17Instituto Investigación Sanitaria Aragón (IISA), Universidad de Zaragoza (UNIZAR), Zaragoza, Spain; 18Hôpital Jean Minjoz, Doubs, France; 19Hospital Universitario Virgen del Rocío, Sevilla, Spain; 20Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; 21Department of Oncology and Hemato-Oncology (DIPO), University of Milan, Milan, Italy; 22International Breast Cancer Center (IBCC), Pangaea Oncology, Quiron Group, Barcelona, Spain; 23Department of Medicine, Faculty of Biomedical and Health Sciences, Universidad Europea de Madrid, Madrid, Spain; 24IOB Madrid, Hospital Beata María Ana, Madrid, Spain;Related Articles
Omitting Regional Nodal Irradiation after Response to Neoadjuvant Chemotherapy
No need for radiation if neoadjuvant therapy led to a complete response in the lymph nodes.
Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer
The INAVO120 trial assessed inavolisib + palbociclib–fulvestrant vs placebo plus palbociclib–fulvestrant in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer, showing significant improvements in progression-free survival (PFS) (15.0 vs 7.3 months) and overall survival (OS) (34.0 vs 27.0 months). The triplet regimen achieved a higher overall response rate (ORR) (62.7% vs 28.0%), establishing it as a potential new standard for this endocrine-resistant population. Notably, side effects like hyperglycemia, stomatitis, diarrhea, and ocular effects were more frequent with inavolisib.
Chemotherapy-free neoadjuvant pembrolizumab combined with trastuzumab and pertuzumab in HER2-enriched early breast cancer (WSG-KEYRICHED-1): a single-arm, phase 2 trial
The WSG-KEYRICHED-1 phase II trial evaluated a chemotherapy-free neoadjuvant regimen of pembrolizumab plus trastuzumab and pertuzumab in HER2-enriched early breast cancer, achieving a pathological complete response (pCR) rate of 46.5% (95% CI 31.2–62.6%). No survival data (e.g., EFS or OS) were reported, but the regimen showed an acceptable safety profile with no new cardiac toxicity signals. The chemo-free approach suggests promising potential for de-escalation in this subtype, but we’ll need randomized trials to confirm its efficacy and safety.
Metronomic Capecitabine Plus Aromatase Inhibitor as Initial Therapy in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: The Phase III MECCA Trial
Metronomic dose: low dose cytotoxic therapy at high frequency was studied in combination with an AI (cape at 500mg TID) and showed superiority over AI single agent, this may be an option for patients not tolerating CKD4/6 inhibitors.